MaxCyte (NASDAQ:MXCT) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of MaxCyte (NASDAQ:MXCT) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other brokerages have also commented on MXCT. Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a research report on Friday, April 24th. Craig Hallum dropped their target price on MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, MaxCyte presently has an average rating of “Hold” and a consensus target price of $5.50.

MaxCyte Stock Down 4.6%

Shares of NASDAQ MXCT opened at $1.04 on Friday. MaxCyte has a 12 month low of $0.64 and a 12 month high of $2.40. The company has a market cap of $111.40 million, a price-to-earnings ratio of -2.81 and a beta of 1.37. The business has a fifty day simple moving average of $0.81 and a 200-day simple moving average of $1.14.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Tuesday, May 12th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.06. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%.The business had revenue of $6.22 million during the quarter, compared to the consensus estimate of $7.28 million. As a group, sell-side analysts expect that MaxCyte will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Capricorn Fund Managers Ltd acquired a new position in shares of MaxCyte during the 1st quarter valued at about $5,760,000. Mirabella Financial Services LLP increased its holdings in shares of MaxCyte by 24.2% during the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock valued at $12,956,000 after acquiring an additional 1,600,000 shares during the last quarter. State Street Corp increased its holdings in shares of MaxCyte by 4.0% during the 4th quarter. State Street Corp now owns 2,358,384 shares of the company’s stock valued at $3,655,000 after acquiring an additional 91,534 shares during the last quarter. AXA S.A. increased its holdings in shares of MaxCyte by 123.2% during the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock valued at $4,801,000 after acquiring an additional 1,215,481 shares during the last quarter. Finally, Brooklands Fund Management Ltd acquired a new position in shares of MaxCyte during the 1st quarter valued at about $1,538,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.